Ticker
ACHL

Price
0.95
Stock movement up
+0.03 (3.57%)
Company name
Achilles Therapeutics PLC ADR
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
37.27M
Ent value
-112.75M
Price/Sales
-
Price/Book
0.19
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-3.29%
3 year return
-58.70%
5 year return
-
10 year return
-
Last updated: 2024-05-17

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

DIVIDENDS

ACHL does not pay dividends or no data was received

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book0.19
EV to Sales-

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count39.32M
EPS (TTM)-1.81
FCF per share (TTM)-0.46

Income statement

Loading...
Income statement data
Revenue (TTM)0.00
Gross profit (TTM)0.00
Operating income (TTM)-78.38M
Net income (TTM)-71.18M
EPS (TTM)-1.81
EPS (1y forward)-1.50

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-
Profit margin (TTM)-

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash173.34M
Net receivables16.00M
Total current assets196.58M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets220.36M
Accounts payable5.19M
Short/Current long term debt8.58M
Total current liabilities17.99M
Total liabilities23.31M
Shareholder's equity197.04M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-37.04M
Capital expenditures (TTM)3.60M
Free cash flow (TTM)-18.14M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-36.12%
Return on Assets-32.30%
Return on Invested Capital-35.37%
Cash Return on Invested Capital-9.02%

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open0.93
Daily high0.96
Daily low0.90
Daily Volume116K
All-time high17.86
1y analyst estimate9.00
Beta-
EPS (TTM)-1.81
Dividend per share-
Ex-div date-
Next earnings date2 Aug 2024

Downside potential

Loading...
Downside potential data
ACHLS&P500
Current price drop from All-time high-94.69%-0.06%
Highest price drop-95.80%-56.47%
Date of highest drop30 Apr 20249 Mar 2009
Avg drop from high-81.08%-11.32%
Avg time to new high395 days13 days
Max time to new high786 days1805 days

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
ACHL (Achilles Therapeutics PLC ADR) company logo
Marketcap
37.27M
Marketcap category
Small-cap
Description
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.
Employees
234
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...